iBio (NYSEMKT:IBIO) Shares Up 8.3% – Still a Buy?

iBio, Inc. (NYSEMKT:IBIOGet Free Report)’s stock price shot up 8.3% during mid-day trading on Friday . The stock traded as high as $2.35 and last traded at $2.35. 1,928,910 shares changed hands during trading, an increase of 1,604% from the average session volume of 113,212 shares. The stock had previously closed at $2.17.

iBio Stock Performance

The firm has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.10. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $60.71 million, a price-to-earnings ratio of -1.94 and a beta of 1.14.

iBio Company Profile

(Get Free Report)

iBio, Inc is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.

The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases.

Recommended Stories

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.